CRISPR Therapeutics (CRSP) Soars 9.6% on Positive Pipeline Data

CRISPR Therapeutics AG (CRSP) shares surged 9.6% to $60.08, driven by high trading volume and positive sentiment on its pipeline. Updated data on CTX310 showed significant reductions in LDL and TG levels, boosting excitement around the company’s other pipeline candidates.

CRISPR Therapeutics is expected to report a quarterly loss of $1.54 per share, with revenues of $5.89 million, up 1032.9% YoY. Consensus EPS estimate has remained steady, indicating potential strength. The stock carries a Zacks Rank #3 (Hold) in the Medical – Biomedical and Genetics industry.

Wave Life Sciences (WVE) closed 10.8% higher at $7.7, with a consensus EPS estimate of -$0.28, down -6.6% in the past month. The Zacks Rank for WVE is #3 (Hold) in the same industry. For more stock insights and potential breakout opportunities, check out the latest Zacks Rank #1 (Strong Buy) stocks.

Looking for more stock recommendations and insights? Download the free report “7 Best Stocks for the Next 30 Days” from Zacks Investment Research. Discover potential breakout opportunities and get ahead of the market trends. Stay informed with the latest stock picks and analysis from Zacks.

Original article published by Zacks Investment Research. The views expressed are those of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more at Nasdaq: CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last?